Market Capitalization: Immunocore Holdings plc (IMCR)

immunocore.com (IMCR) - corporate logo

The growth in value of Immunocore Holdings plc (IMCR) is driven by sales of a unique ocular melanoma drug and successes in lung cancer therapy, while its monopoly status in treating rare tumors allows the company to flexibly manage its pricing power. This historical price chart demonstrates the dynamics of the asset, whose market capitalization currently stands at 1.49. Simultaneously, the business is implementing automated dosing systems to accelerate the screening of new oncology drugs.

IMCR Immunocore: Market Value in the range 07/04/2022 - 11/17/2026

Immunocore Holdings plc - analytical breakdowns and key metrics (IMCR)

- market price and analyst price targets:
Analysis of all company metrics:IMCR (immunocore.com)
Original product of Immunocore Corp

Immunocore Holdings plc (IMCR) strategic alliances in cancer immunotherapy and the synergy of the ImmTAX platform are accelerating time-to-market for drugs, establishing a foundation for business value growth. By analyzing the company's market capitalization, an investor assesses the aggregate value of all shares, which allows for the identification of systemic degradation or the confirmation of price stability through market recognition of the issuer's fundamental potential.